SparingVision Conference Participation in H2 2025
Paris, 2 July 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today announced upcoming conferences that its management team will be participating in in the second half of 2025:
Investor and Industry Conferences:
Oppenheimer Private Life Science Company Showcase, virtual – 25 September
TOPRA Annual Symposium, Berlin, Germany – 29 September-1 October
Chardan’s 9th Annual Genomic Medicines Conference, New York, NY, USA – 21 October
Jefferies London Healthcare Conference, London, UK – 19-21 November
Scientific & Medical Conferences:
Euretina (European Society of Retina Specialists), Paris, France – 4-7 September
Retina Society Annual Meeting, Chicago, USA – 10-13 September
ISGEDR, Oslo, Norway – 11-13 September
Retinal Degeneration Meeting, Prague, Czech Republic – 15-19 September
European Society of Gene and Cell Therapy, Sevilla, Spain – 7-10 October
American Academy of Ophthalmology, Orlando, USA – 17-20 October
Advanced Therapies USA, Philadelphia, USA – 18-19 November
**ENDS**
NOTES TO EDITORS
Contacts:
Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)
Media: ICR Healthcare (sparingvision@icrhealthcare.com)
About SparingVision
SparingVision is a clinical-stage genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for blinding retinal diseases. Its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP) and geographic atrophy secondary to dry-AMD, two leading causes of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X @SparingVision